Journal Article

FZJ-2026-00869

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design

Kotecha, R. (Corresponding author) ; Akdemir, E. Y. ; Kutuk, T. ; Ilgın, C. ; Ahluwalia, M. S. ; Bi, W. L. ; Blakeley, J. ; Dixit, K. S. ; Dunn, I. F. ; Galanis, E. ; Galldiks, N.FZJ* ; Huang, R. Y. ; Johnson, D. R. ; Kaley, T. J. ; Kamson, D. O. ; Kurz, S. C. ; McDermott, M. W. ; Odia, Y. ; Preusser, M. ; Raizer, J. ; Reardon, D. A. ; Rogers, C. L. ; Ruda, R. ; Schiff, D. ; Vogelbaum, M. A. ; Weller, M. ; Wen, P. Y. ; Mehta, M. P.

2025
Oxford Univ. Press Oxford

This record in other databases:  

Please use a persistent id in citations: doi:10.1093/neuonc/noaf009  doi:10.34734/FZJ-2026-00869

Abstract: Background. Despite advances in our understanding of the molecular underpinnings of meningioma progressionand innovations in systemic and local treatments, recurrent meningiomas remain a substantial therapeutic challenge.The objective of this systematic review and meta-analysis is to provide a historical baseline, contemporaryanalysis, and propose a “rate of probable interest” to inform future clinical trial design and development on behalfof the Response Assessment in Neuro-Oncology meningioma group.Methods. PubMed, ClinicalTrials.gov, and ASCOpubs databases were screened for clinical trials evaluating theactivity of systemic therapies for adults with recurrent meningiomas. The pooled progression-free survival at6-months and 1-year (PFS-6 and PFS-1 year) values were calculated using the random effects technique withI2 indices.Results. The pooled PFS-6 and PFS-1 year rates for recurrent WHO grade 1 meningiomas were 43.6% (95% CI:22.7-67.0%, I2 = 80%) and 21.7% (95% CI: 6.2-53.9%, I2 = 76%), and for grades 2-3 meningiomas, the PFS-6 was 38.0%(95% CI: 28.3-48.8%, I2 = 68%). In the targeted therapy group, PFS-6 and PFS-1 year rates stood at 62.0% (I2 = 58%)and 49.0% (I2 = 63%) for grade 1, while for grades 2-3 tumors, the PFS-6 rates with targeted therapy and immunotherapywere 42.1% (I² = 60%) and 46.0% (I² = 0%), respectively. The benchmarks were set at 67% and 54% for PFS-6and PFS-1 year for grade 1 tumors, and PFS-6 of 49% for grades 2-3 tumors.Conclusions. Several studies have reported outcomes in patients with recurrent meningiomas testing a variety ofagents with modest, but variable and progressively increasing activity. In this context, we recommend new benchmarksfor future trials to define efficacy of future investigational therapies.

Note: Neuro Oncol . 2025 Sep 8;27(7):1670-1685.Funding: none declared

---

Contributing Institute(s):

1. Kognitive Neurowissenschaften (INM-3)

Research Program(s):

1. 5252 - Brain Dysfunction and Plasticity (POF4-525) (POF4-525)

---

Database coverage:
; ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF >= 15 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---